Search tips
Search criteria 


Logo of ajrcmbIssue Featuring ArticlePublisher's Version of ArticleSubmissionsAmerican Thoracic SocietyAmerican Thoracic SocietyAmerican Journal of Respiratory Cell and Molecular Biology
Am J Respir Cell Mol Biol. 2012 June; 46(6): 765–772.
PMCID: PMC3380285

Thy-1 Signals through PPARγ to Promote Lipofibroblast Differentiation in the Developing Lung


Thy-1 is a glycosylphosphytidylinositol-linked cell-surface glycoprotein present on a subset of lung fibroblasts, which plays an important role in postnatal alveolarization. In the present study, we define the role of Thy-1 in pulmonary lipofibroblast differentiation and in the regulation of lipid homeostasis via peroxisome proliferator–activated receptor–γ (PPARγ). Thy-1 was associated with interstitial cells containing lipid droplets in vivo. The transfection of Thy-1 into Thy-1 (−) fibroblasts increased triglyceride content, fatty-acid uptake, and the expression of the lipofibroblast marker adipocyte differentiation–related protein. Thy-1 (+) fibroblasts exhibited 2.4-fold higher PPARγ activity, and the inhibition or activation of PPARγ reduced and increased triglyceride content, respectively. Thy-1 (−) fibroblasts were not responsive to either of the PPARγ agonists ciglitazone or prostaglandin J2, supporting the importance of Thy-1 in signaling via PPARγ. Thy-1 (+) fibroblasts expressed significantly higher concentrations of fatty-acid transporter protein–3 mRNA, and demonstrated higher rates of fatty-acid uptake and increased triglyceride content. The inhibition of fatty-acid transporter protein function reduced Thy-1 (+) fibroblast lipid content. The expression of Thy-1 in C57BL/6 lung fibroblasts increased during the neonatal period, coinciding with the onset of alveolarization. Thy-1 promoted lipofibroblast differentiation via the expression of PPARγ, stimulated lipid accumulation via fatty-acid esterification, and enhanced the fatty-acid uptake mediated by fatty-acid transporter proteins. Thy-1 is important in the regulation of lipofibroblast differentiation in the developing lung.

Keywords: Thy-1, lipofibroblast, PPARγ, lipid metabolism

Clinical Relevance

Pulmonary lipofibroblasts are important in alveolar development, and the peroxisome proliferator–activated receptor–γ (PPARγ) is known to induce lipofibroblast differentiation. However, little is known about the factors that activate PPARγ in pulmonary fibroblasts. This study demonstrates that pulmonary fibroblast Thy-1 expression induces lipofibroblast differentiation through PPARγ, and describes a mechanism by which pulmonary fibroblasts accumulate neutral lipid.

Beginning at 35 weeks after conception and continuing for up to 8 years after birth, the alveolar stage of lung development is marked by the sequential division of larger airspaces into smaller ones by secondary alveolar septa (1, 2). From term birth until adulthood, the 5-fold increase in the number of alveoli and the 20-fold increase in alveolar surface area are critical in meeting the increasing oxygenation and ventilation needs of human growth and activity (2, 3). Premature birth, exposure to high concentrations of inspired oxygen, and mechanical ventilation lead to impaired alveolar development and chronic lung disease (4). The impaired lung function of chronic lung disease results in significant morbidity, mortality, and healthcare costs from early life through adulthood (58). Understanding how the different tissues of the lung behave during normal and impaired alveolar development is a key first step toward restoring alveolarization and attenuating the burden of respiratory disease after premature birth.

Pulmonary lipofibroblasts comprise an incompletely characterized population of lipid-containing interstitial cells that play an important role in alveolarization. Hyperoxia, hypoxia, and nicotine exposure stimulate lipofibroblasts to myofibroblast differentiation and impair alveolar development (912). Peroxisome proliferator–activated receptor–γ (PPARγ) signaling is important in lipofibroblast differentiation (13, 14), and PPARγ agonists can reverse lipofibroblast to myofibroblast differentiation and restore alveolar development in murine and rat models (10, 15). The only described signaling pathway upstream of PPARγ that promotes fibroblast lipid accumulation is the parathyroid-related peptide–leptin axis (16), although a recent report questioned the importance of lipofibroblast leptin signaling (17). To understand the key events in alveolar development, a broader understanding of the endogenous factors that promote lipofibroblast differentiation is needed.

Thy-1 is a glycophosphatidyl inositol–linked glycoprotein critical in the determination of pulmonary fibroblast phenotype (18, 19). Pulmonary fibroblast Thy-1 expression has been associated with the presence of lipid inclusions (20, 21), and the loss of pulmonary fibroblast Thy-1 expression causes myofibroblast differentiation (18, 2224). Although the lungs of Thy-1/ and wild-type mice are similar at birth, postnatal alveolar septation is impaired in the Thy-1/ mouse (25). Whether Thy-1 stimulates or is merely associated with lipid accumulation in pulmonary fibroblasts remains unknown. Because Thy-1 is a key regulator of pulmonary fibroblast phenotype and important in alveolar development, we hypothesized that Thy-1 signaling stimulates lipofibroblast differentiation through PPARγ, and that fibroblast Thy-1 expression increases at the onset of alveolarization.

Materials and Methods

Please see the online supplement for more detailed descriptions of materials and methods.

Animal Use

C57BL/6 wild-type (WT) and Thy-1/ mice on a C57BL/6 background (Dr. Roger Morris, King's College, London, UK) were used, with approval by our institutional Animal Care and Use Committees.

Lung Histology and Thy-1 Expression

The lungs of mice at serial gestational ages from Postnatal Day (PND) 1 to 8 weeks were immunostained for Thy-1. Snap-frozen lungs of mice at PND5 and PND14 were immunostained for Thy-1, costained with oil–red-O, and evaluated by fluorescence microscopy.

Lung Triglyceride Content

Lungs of WT and Thy-1/ PND5 and PND14 mice were stained with oil–red-O, and the numbers of lipid inclusions in five ×40 fields were counted. The neutral lipid contents of lung homogenates from WT and Thy-1/ mice were analyzed using the Wako triglyceride assay (Wako, Richmond, VA).

Cells and Tissue Culture Conditions

Sorted fibroblasts.

PND14 WT fibroblasts were isolated and sorted for Thy-1, as described in the online supplement. Fibroblasts were analyzed by FACS for the maintenance of Thy-1 expression and used at a total passage number of six.

Transfected fibroblasts.

To isolate the effects of Thy-1 on fibroblast phenotype, a previously described transfection model was used (26). Fetal rat lung fibroblasts, which are entirely Thy-1–negative (RFL6; American Type Culture Collection, Manassas, VA), were transfected with a control vector (RFL6.EV) or the murine Thy-1.2 vector (RFL6.CD90).

Both sorted fibroblasts and Thy-1–transfected fibroblasts were used for tissue-culture experiments. To determine the effects of Thy-1 on PPARγ activity and lipid metabolism, ciglitazone, prostaglandin J2, the PPARγ inhibitor GW9662, and the fatty-acid transporter inhibitor phloretin were used. Thy-1 knockdown was achieved in Thy-1–transfected fibroblasts, using Thy-1 Silencer Select silencing (si) RNA (Invitrogen, Carlsbad, CA) or control siRNA.

PPARγ Luciferase Assay

A previously described PPARγ luciferase reporter plasmid (27) and renilla luciferase control plasmid were transfected into RFL6.CD90 and RFL6.EV cells. After overnight transfection, cells were grown in 10% FBS-containing media for 48 hours, and the cell lysate was collected for analysis.

Fibroblast Triglyceride Content

Thy-1 sorted or transfected fibroblasts were serum-starved for 24 hours, and then grown in 10% FBS containing media for 48 hours. Cells were collected, washed, and lysed. The lysate was centrifuged, its volume was normalized for the number of cells, and the supernatant was analyzed for triglyceride content.

Fatty-Acid Uptake

To quantitate fatty-acid uptake, sorted and transfected fibroblasts were serum-starved for 24 hours. The media were aspirated, and fatty-acid uptake was quantitated using the QBT Fatty Acid Uptake Assay (Molecular Devices, Sunnyvale, CA).

Quantitative PCR and Western Blotting

Thy-1–transfected fibroblasts were used to assess how Thy-1 alters the mRNA and protein expression of lipofibroblast-related genes. Taqman RT-PCR was performed using the validated primers listed in the online supplement. The protein expression of adipocyte differentiation–related protein, PPARγ, and β-actin was determined by Western blotting.

Metabolic Activity

The metabolic activity of transfected RFL6 cells was determined using the WST-1 assay (Roche, Branford, CT), according to the manufacturer's instructions.

Statistical Analysis

Statistical comparisons between groups were performed using the Student's t test or one-way ANOVA according to the Holm-Sidak method. P < 0.05 was considered significant.


Fibroblast Thy-1 Expression Increases at the Onset of Alveolarization

We previously reported that whole-lung Thy-1 mRNA increased with development, but the localization of Thy-1 expression to pulmonary fibroblasts remained unclear (25). By immunohistochemistry, Thy-1 stained principally in the interstitium, and the number of brown/purple-staining cells increased during development (Figure 1A). Pulmonary fibroblasts from mice at sequential ages were assessed for Thy-1 expression by FACS. Isolated fibroblasts were negative for the macrophage markers CD11b and F4/80, the epithelial marker E-cadherin, and the endothelial marker CD31 (see Figure E1 in the online supplement). The percentage of fibroblasts expressing Thy-1 increased in a bimodal pattern from fewer than 5% positive fibroblasts at post-fertilization day 18.5 (E18.5) to 70% in adulthood (Figure 1B). These data show that pulmonary fibroblast Thy-1 expression increases coincident with the onset of alveolarization.

Figure 1.
Pulmonary fibroblast Thy-1 expression is developmentally regulated, and Thy-1 colocalizes with interstitial lipid droplets. (A) Immunohistochemistry for Thy-1 reveals that expression in pulmonary interstitial cells increases throughout alveolarization. ...

Thy-1 Expression Is Associated with Neutral Lipid Accumulation in Primary Lung Fibroblasts

Previous studies reported the association of Thy-1 with pulmonary fibroblast lipid droplets, but the lipid content was not quantitated. Thy-1 colocalized with lipid droplets in oil–red-O–stained PND5 lung sections (Figure 1C). Lung fibroblasts (PND14) sorted for Thy-1 maintained Thy-1 expression with passaging (Figure 2A). Thy-1 (+) sorted fibroblasts contained 111% more triglyceride than Thy-1 (−) sorted fibroblasts (Figure 2B), demonstrating that in pulmonary fibroblasts, the expression of Thy-1 is associated with increased fibroblast lipid content.

Figure 2.
Thy-1 induces neutral lipid accumulation in pulmonary fibroblasts. (A) Isolated murine lung fibroblasts sorted for Thy-1 (black) maintain Thy-1 expression in vitro. (B) Thy-1 (+) murine lung fibroblasts (solid bar) have significantly higher lipid content ...

Thy-1 Expression Stimulates Neutral Lipid Accumulation in Pulmonary Fibroblasts

A heterologous expression model was used to ascertain the role of Thy-1 fibroblast lipid accumulation. Thy-1–transfected fibroblasts (RFL6.CD90) contained substantially more and larger lipid droplets than empty vector–transfected fibroblasts (RFL6.EV) (Figure 2C). RFL6.CD90 fibroblasts maintained their expression with passaging, and contained 331% more triglyceride than RFL6.EV fibroblasts (Figures 2D and 2E). The knockdown of Thy-1 in RFL6.CD90 fibroblasts using Thy-1 siRNA reduced triglyceride content by 52%, compared with control siRNA–transfected fibroblasts (Figures 2F and 2G), indicating that Thy-1 signaling stimulates neutral lipid accumulation in pulmonary fibroblasts.

The Thy-1−/− Mouse Does Not Have Reduced Numbers of Interstitial Lipid Droplets

Whether the in vitro finding that Thy-1 (+) fibroblasts contain larger and more numerous lipid droplets is also true in vivo remains unknown. On PND5, Thy-1/ murine lungs contained more lipid droplets than did WT lungs, but on PND14, the numbers of lipid droplets were similar (Figures E2A–E2E). The total lung lipid content of Thy-1/ mice on PND14 is less than for WT mice (Figure E2F). Lipid droplets were not present in alveolar Type II cells, as seen in other models of dysregulated pulmonary fibroblast lipid metabolism (Figure E3) (28). The deletion of Thy-1 in the Thy-1/ mouse is not pulmonary fibroblast–specific, and in vitro findings from isolated fibroblasts may not represent in vivo conditions.

Thy-1 Increases PPARγ Expression, Activity, and PPARγ-Mediated Neutral Lipid Accumulation

PPARγ is a well-described regulator of lipofibroblast differentiation, but whether Thy-1 alters PPARγ expression or activity remains unknown. By overexpressing Thy-1 in RFL6 fibroblasts (RFL6.CD90), PPARγ mRNA expression was increased 88%, and protein expression increased 93%, compared with Thy-1–deficient RFL6.EV fibroblasts (Figures 3A and 3B). Adipocyte differentiation–related peptide (ADRP) is both a downstream target of PPARγ and a lipofibroblast marker. ADRP may play an independent role in pulmonary fibroblast lipid accumulation, insofar as 3T3 fibroblasts overexpressing ADRP accumulate lipid in a PPARγ-independent manner (29). ADRP mRNA expression was increased 80%, and protein content increased 930%, in RFL6.CD90 fibroblasts compared with RFL6.EV fibroblasts (Figures 3C and 3D). As assessed by a PPARγ luciferase assay, PPARγ signaling was increased by 142% in RFL6.CD90 cells compared with RFL6.EV cells (Figure 3F). The PPARγ ligand ciglitazone increased triglyceride content by 80% in a dose-dependent manner in RFL6.CD90 fibroblasts, but no increase in lipid content was evident in RFL6.EV fibroblasts (Figure 3G). The inhibition of PPARγ signaling with GW9662 reduced triglyceride content by 62% in RFL6.CD90 fibroblasts (Figure 3H). To test whether the lack of ciglitazone response in RFL6.EV fibroblasts was attributable to reduced PPARγ expression or an inhibition of PPARγ signaling, the PPARγ response element ligand prostaglandin J2 (PGJ2) was used. PGJ2 did not increase triglyceride content in RFL6.EV fibroblasts until a threshold concentration of 8–10 nM was achieved, at which point the triglyceride content increased by 710% (Figure 3I). Cell viability was not altered by the reported concentrations of ciglitazone, GW9662, or PGJ2. Doses of ciglitazone (1 μM and greater) and combinations of ciglitazone and GW9662 reduced cell viability. These data demonstrate that Thy-1 increases the expression of PPARγ, increases PPARγ signaling, and increases PPARγ-mediated neutral lipid accumulation.

Figure 3.
Thy-1 up-regulates peroxisome proliferator–activated receptor–γ (PPARγ) and adipocyte differentiation–related peptide (ADRP) expression in pulmonary fibroblasts, and induces pulmonary fibroblast neutral lipid accumulation ...

Thy-1 Increases Expression of the PPARγ Heterodimer Retinoid X Receptor–α

PPARγ must heterodimerize with retinoic-acid receptors to activate the PPARγ response element (30), and the retinoid X receptor–α (RXRα) is important in alveolar development (31). RXRα mRNA was increased by 38% in RFL6.CD90 cells compared with RFL6.EV cells (Figure E4A). RXRα can also heterodimerize with the liver X receptor α (LXRα), which regulates many lipid metabolic processes (30), and which causes keratinocyte lipid accumulation (32). The expression of LXRα was decreased by 61% in RFL6.CD90 fibroblasts, compared with RFL6.EV fibroblasts (Figure S4AB). These data suggest that Thy-1 (+) fibroblasts possess a greater abundance of the PPARγ–RXRα heterodimer.

Thy-1/PPARγ Signaling Increases Fibroblast Lipid Content through Increased Fatty-Acid Transporter Protein Expression and Increased Fatty-Acid Esterification

Although both PPARγ (10, 13, 14) and ADRP (29) play a role in the development of the lipofibroblast phenotype, the mechanism by which lipid enters and accumulates in fibroblasts remains unknown. One potential mechanism involves the hydrolysis of triglyceride at the cell membrane and the transport of liberated fatty acids. Lipoprotein lipase is expressed by lipofibroblasts (33), and its transcription is positively regulated by PPARγ (30). However, lipoprotein lipase mRNA was not detected in RFL6.EV or RFL6.CD90 fibroblasts by quantitative PCR. Another potential mechanism of lipid accumulation in Thy-1 (+) fibroblasts involves the uptake of free fatty acids liberated by adjacent cells (potentially endothelial cells). RFL6.CD90 fibroblasts took up 40% more free fatty acid than did RFL6.EV fibroblasts (Figure 4A), and the siRNA knockdown of Thy-1 in RFL6.CD90 fibroblasts reduced fatty-acid uptake (Figure 4B), indicating that the presence of Thy-1 increases the transport of free fatty acids into pulmonary fibroblasts.

Figure 4.
Thy-1 increases pulmonary fibroblast free fatty-acid uptake by increased expression and activity of fatty-acid transporter proteins. (A) RFL6.CD90 fibroblasts (solid circles) take up more free fatty acid than do EV fibroblasts (open circles). (B) The ...

Fatty acids can enter cells via either active transport or facilitated diffusion. Active transport occurs via fatty-acid translocase (CD36). CD36 is expressed by alveolar Type II cells (34), and is regulated by PPARγ (30). However, in RFL6.CD90 fibroblasts, CD36 was detected by neither quantitative PCR nor FACS (with gating based on an isotype control; data not shown). Fatty-acid transporter proteins allow for the facilitated diffusion of fatty acids, and are positively regulated by PPARγ (35). Two of these proteins are expressed in the lung: solute carrier family 27, member 1 and member 3 (SLC27A1 and SLC27A3) (36, 37). SLC27A1 mRNA expression was not statistically different between RFL6.CD90 and RFL6.EV fibroblasts, whereas SLC27A3 mRNA was 82% higher in RFL6.CD90 fibroblasts (Figures 4C and 4D). This finding suggests that fatty-acid transport through SLC27A3 at least partly accounts for differences in fatty-acid uptake between RFL6.CD90 and RFL6.EV fibroblasts. To test whether fatty-acid transporter proteins, including SLC27A3, are important mediators of fatty-acid uptake in Thy-1 (+) fibroblasts, fatty-acid uptake was measured in the presence of increasing concentrations of phloretin, an inhibitor of these transporters. Phloretin decreased fatty-acid uptake by 53% (Figure 4E), and triglyceride content by 77% (Figure 4F), in RFL6.CD90 fibroblasts. Toxicity was evident with doses of phloretin at 50 μM and above. These findings support the concept that fatty-acid transporter proteins, which are inhibited by phloretin, are likely to mediate increased fatty-acid uptake and influence the increased lipid content in Thy-1 (+) pulmonary fibroblasts.

Because fatty-acid transporter proteins facilitate only the passive transport of fatty acids, a gradient is required for fatty- acid transport. Two processes could generate this gradient: fatty-acid oxidation or fatty-acid esterification. To test for increased fatty-acid oxidation in Thy-1 (+) fibroblasts, we determined metabolic activity under serum-free conditions (i.e., the same conditions used in the fatty-acid uptake assay). The WST-1 assay assesses metabolic activity by photometrically measuring the mitochondrial production of nicotinamide adenine dinucleotide phosphate-reduced. RFL6.CD90 fibroblasts cleaved 24% less WST-1, indicating reduced metabolic activity in RFL6.CD90 fibroblasts compared with RFL6.EV fibroblasts (Figure 5A). Fatty-acid esterification involves the creation of an ester moiety from a fatty-acid carboxyl group and a glycerol hydroxyl group. We assessed the expression of two key fatty-acid esterifying enzymes: cytidine diphospo (CDP)-diacylglyerol synthase (CDS1) and monoacylglycerol acyltransferase (MOGAT1). The expression of CDS1 was increased by 167% (Figure 5B), and the expression of MOGAT1 was increased by 22%, in Thy-1–transfected cells (Figure 5C). These data suggest that increased fatty-acid esterification into triacylglycerol, but not increased fatty-acid oxidation, creates the diffusion gradient by which fatty acids enter Thy-1 (+) pulmonary fibroblasts.

Figure 5.
Thy-1 (+) fibroblasts have greater expression of fatty-acid esterifying enzymes and lower metabolic activity than Thy-1 (−) fibroblasts. (A) Under serum-starved conditions, RFL6.CD90 fibroblasts (solid bar) are less metabolically active than RFL6.EV ...


In this study, we show that Thy-1 stimulates lipofibroblast differentiation through the activation of PPARγ. The overexpression of Thy-1 in Thy-1 (−) pulmonary fibroblasts increased the expression of PPARγ and its heterodimer RXRα, increased the expression of the lipofibroblast marker ADRP, and increased fibroblast lipid content. The inhibition of PPARγ reduced the lipid content of Thy-1 (+) fibroblasts. These findings are consistent with previous observations that PPARγ signaling promotes a lipofibroblast phenotype (9, 11), and demonstrate the novel finding that PPARγ signaling is modulated by lung fibroblast Thy-1 expression.

The expression of Thy-1 by lung fibroblasts increased at the onset of alveolarization, perhaps indicating an important role in alveolarization. This pattern is consistent with the observation that alveolarization is delayed in Thy-1/ mice (25). However, our findings differ from those in previous reports that indicate an earlier appearance of the pulmonary lipofibroblast (38, 39), suggesting that the Thy-1 (+) lipofibroblast represents a distinct cell population. This assertion is supported by two observations. First, Awonusonu and colleagues found that not all lipofibroblasts are Thy-1 (+) (38). Second, whereas the earlier-appearing lipofibroblast population was shown to be important in surfactant production in vitro (40, 41), Thy-1/ mouse pups do not exhibit respiratory distress or lung histology consistent with surfactant deficiency (10, 25, 42). The prevention of lipofibroblast-to-myofibroblast differentiation by the prenatal administration of rosiglitazone increased the numbers of lamellar bodies in alveolar Type II cells in rats on PND1 (43), supporting the assertion that earlier-appearing lipofibroblasts may play a role in surfactant production, but the later-appearing Thy-1 (+) lipofibroblasts do ;not.

Despite in vitro evidence for the role of Thy-1 in lipofibroblast differentiation, Thy-1−/− mice do not have lower numbers of lipid droplets in vivo. Because all cells in this murine model are deficient in Thy-1, we cannot isolate its role in fibroblast lipid accumulation in vivo from the effects exerted by neighboring cells. Alveolar Type II cells also express Thy-1 (44), and the epithelium overlying Thy-1 (−) fibroblasts in idiopathic pulmonary fibrosis demonstrates an increased expression of Thy-1 (45). Because alveolar epithelial–mesenchymal signaling is important in lipofibroblast differentiation and function (18), and the potential effects of Thy-1 on epithelial cell functions are unknown, a fibroblast-specific Thy-1 knockout mouse would be required to determine the cell-specific effects of Thy-1 on fibroblast phenotype in vivo.

The present study supports the concept that Thy-1 (+) fibroblasts increase lipid content via facilitated diffusion via fatty-acid transporter proteins. Thy-1 (+) fibroblasts demonstrate greater fatty-acid uptake and a higher expression of the fatty-acid transporter protein SLC27A3. The inhibition of fatty-acid transporter proteins with phloretin decreases both fatty-acid transport and triglyceride content in Thy-1 (+) fibroblasts. the increased expression of fatty-acid esterifying enzyme CDP-diacylglycerol synthase in Thy-1 (+) fibroblasts may create the necessary fatty-acid diffusion gradient. This mechanism of lipid accumulation is distinct from that of adipocytes (37) and keratinocytes (32), and demonstrates the unique biology of the Thy-1 (+) lipofibroblast. Pulmonary fibroblasts seem to have biological characteristics distinct from myometrial or orbital fibroblasts, because the expression of Thy-1 in those tissues does not seem to stimulate lipid accumulation (4648). A schematic depiction of the proposed mechanism for lipid accumulation in Thy-1 (+) pulmonary lipofibroblasts is presented in Figure 6.

Figure 6.
Proposed mechanism by which Thy-1 increases pulmonary fibroblast lipid content. Thy-1 increases the transcription of PPARγ and retinoic X receptor–α (RXRα), and also activates PPARγ. PPARγ up-regulates the ...

In conclusion, we have demonstrated that Thy-1 promotes lipofibroblast differentiation via PPARγ, that it acts to increase fibroblast triglyceride content via fatty-acid transporter proteins, and that its developmental regulation is consistent with an important role in alveolar development. The Thy-1 (+) lipofibroblast represents a unique subpopulation, and the manipulation of Thy-1 expression or associated signaling pathways could improve alveolar development after premature births.

Supplementary Material

Online Supplement:


B.M.V. performed this work both at the University of Alabama at Birmingham and at Cincinnati Children's Hospital Medical Center. Sheng Liu at the Cincinnati Children's Hospital Research Foundation assisted with tissue processing, immunofluorescence, and immunohistochemistry. Brian H. Halloran at the University of Alabama at Birmingham provided sorted Thy-1 fibroblasts from 14-day-old C57BL/5 mice. Mark MacEwen at the University of Alabama at Birmingham provided technical guidance and assistance with tissue-culture experiments. Patrick Lanhi at the Cincinnati Children's Hospital Research Foundation performed the PPARγ luciferase assay. Basilia Zingarelli at the Cincinnati Children's Hospital Research Foundation generously provided the PPARγ luciferase plasmid.


B.M.V. designed and performed all experiments. N.A. was instrumental in developing flow cytometry experiments. J.A.W. provided extensive editorial support, and assisted in the development of lipid metabolism experiments. J.S.H. was the primary mentor for this project, and was important in developing early experiments with lipid content and fatty acid uptake.

This work was supported by the Dixon Foundation (through Children's Health Systems, Birmingham, Alabama), by the Kaul Pediatric Research Initiative (through Children's Health Systems, Birmingham, Alabama), by National Institutes of Health grants R01-HL082818 (J.S.H.) and R01-HL92906 (N.A.), by American Thoracic Society Fellow Career Development Grant F-09-035 (B.M.V.), by the Translational Research in Normal and Disordered Development Program of the University of Alabama at Birmingham, and by Research Facilities Improvement Program Grant C06RR 15,490 from the National Center for Research Resources.

This article has an online supplement, which is accessible from this issue's table of contents at

Originally Published in Press as DOI: 10.1165/rcmb.2011-0316OC on January 20, 2012

Author disclosures are available with the text of this article at


1. Zoetis T, Hurtt ME. Species comparison of lung development. Birth Defects Res B Dev Reprod Toxicol 2003;68:121–124 [PubMed]
2. Balinotti JE, Tiller CJ, Llapur CJ, Jones MH, Kimmel RN, Coates CE, Katz BP, Nguyen JT, Tepper RS. Growth of the lung parenchyma early in life. Am J Respir Crit Care Med 2009;179:134–137 [PMC free article] [PubMed]
3. Hislop AA, Wigglesworth JS, Desai R. Alveolar development in the human fetus and infant. Early Hum Dev 1986;13:1–11 [PubMed]
4. Baraldi E, Filippone M. Chronic lung disease after premature birth. N Engl J Med 2007;357:1946–1955 [PubMed]
5. Kobaly K, Schluchter M, Minich N, Friedman H, Taylor HG, Wilson-Costello D, Hack M. Outcomes of extremely low birth weight (<1 kg) and extremely low gestational age (<28 weeks) infants with bronchopulmonary dysplasia: effects of practice changes in 2000 to 2003. Pediatrics 2008;121:73–81 [PubMed]
6. Stroustrup A, Trasande L. Epidemiological characteristics and resource use in neonates with bronchopulmonary dysplasia: 1993–2006. Pediatrics 2010;126:291–297 [PubMed]
7. Doyle LW, Faber B, Callanan C, Freezer N, Ford GW, Davis NM. Bronchopulmonary dysplasia in very low birth weight subjects and lung function in late adolescence. Pediatrics 2006;118:108–113 [PubMed]
8. Shi W, Bellusci S, Warburton D. Lung development and adult lung diseases. Chest 2007;132:651–656 [PubMed]
9. Rehan VK, Sakurai R, Wang Y, Santos J, Huynh K, Torday JS. Reversal of nicotine-induced alveolar lipofibroblast-to-myofibroblast transdifferentiation by stimulants of parathyroid hormone–related protein signaling. Lung 2007;185:151–159 [PubMed]
10. Rehan VK, Wang Y, Patel S, Santos J, Torday JS. Rosiglitazone, a peroxisome proliferator–activated receptor–gamma agonist, prevents hyperoxia-induced neonatal rat lung injury in vivo. Pediatr Pulmonol 2006;41:558–569 [PubMed]
11. Rehan V, Torday J. Hyperoxia augments pulmonary lipofibroblast-to-myofibroblast transdifferentiation. Cell Biochem Biophys 2003;38:239–250 [PubMed]
12. Nicola T, Ambalavanan N, Zhang W, James ML, Rehan V, Halloran B, Olave N, Bulger A, Oparil S, Chen YF. Hypoxia-induced inhibition of lung development is attenuated by the peroxisome proliferator–activated receptor–{gamma} agonist rosiglitazone. Am J Physiol Lung Cell Mol Physiol 2011;301:L125–L134 [PubMed]
13. Ferguson HE, Kulkarni A, Lehmann GM, Garcia-Bates TM, Thatcher TH, Huxlin KR, Phipps RP, Sime PJ. Electrophilic peroxisome proliferator–activated receptor-gamma ligands have potent antifibrotic effects in human lung fibroblasts. Am J Respir Cell Mol Biol 2009;41:722–730 [PMC free article] [PubMed]
14. McGowan SE, Jackson SK, Doro MM, Olson PJ. Peroxisome proliferators alter lipid acquisition and elastin gene expression in neonatal rat lung fibroblasts. Am J Physiol 1997;273:L1249–L1257 [PubMed]
15. Dasgupta C, Sakurai R, Wang Y, Guo P, Ambalavanan N, Torday JS, Rehan VK. Hyperoxia-induced neonatal rat lung injury involves activation of TGF-{beta} and WNT signaling and is protected by rosiglitazone. Am J Physiol Lung Cell Mol Physiol 2009;296:L1031–L1041 [PubMed]
16. Torday JS, Torres E, Rehan VK. The role of fibroblast transdifferentiation in lung epithelial cell proliferation, differentiation, and repair in vitro. Pediatr Pathol Mol Med 2003;22:189–207 [PubMed]
17. Sato A, Schehr A, Ikegami M. Leptin does not influence surfactant synthesis in fetal sheep and mice lungs. Am J Physiol Lung Cell Mol Physiol 2011;300:L498–L505 [PubMed]
18. Hagood JS, Prabhakaran P, Kumbla P, Salazar L, MacEwen MW, Barker TH, Ortiz LA, Schoeb T, Siegal GP, Alexander CB, et al. Loss of fibroblast Thy-1 expression correlates with lung fibrogenesis. Am J Pathol 2005;167:365–379 [PubMed]
19. Phipps RP, Baecher C, Frelinger JG, Penney DP, Keng P, Brown D. Differential expression of interleukin 1 alpha by Thy-1+ and Thy-1− lung fibroblast subpopulations: enhancement of interleukin 1 alpha production by tumor necrosis factor-alpha. Eur J Immunol 1990;20:1723–1727 [PubMed]
20. McIntosh JC, Hagood JS, Richardson TL, Simecka JW. Thy1 (+) and (−) lung fibrosis subpopulations in LEW and F344 rats. Eur Respir J 1994;7:2131–2138 [PubMed]
21. Phipps RP, Penney DP, Keng P, Quill H, Paxhia A, Derdak S, Felch ME. Characterization of two major populations of lung fibroblasts: distinguishing morphology and discordant display of Thy 1 and Class II MHC. Am J Respir Cell Mol Biol 1989;1:65–74 [PubMed]
22. Zhou Y, Hagood JS, Murphy-Ullrich JE. Thy-1 expression regulates the ability of rat lung fibroblasts to activate transforming growth factor–beta in response to fibrogenic stimuli. Am J Pathol 2004;165:659–669 [PubMed]
23. Sanders YY, Kumbla P, Hagood JS. Enhanced myofibroblastic differentiation and survival in Thy-1(−) lung fibroblasts. Am J Respir Cell Mol Biol 2007;36:226–235 [PMC free article] [PubMed]
24. Zhou Y, Hagood JS, Lu B, Merryman WD, Murphy-Ullrich JE. Thy-1–integrin alphaV beta5 interactions inhibit lung fibroblast contraction–induced latent transforming growth factor–beta1 activation and myofibroblast differentiation. J Biol Chem 2010;285:22382–22393 [PubMed]
25. Nicola T, Hagood JS, James ML, Macewen MW, Williams TA, Hewitt MM, Schwiebert L, Bulger A, Oparil S, Chen YF, et al. Loss of Thy-1 inhibits alveolar development in the newborn mouse lung. Am J Physiol Lung Cell Mol Physiol 2009;296:L738–L750 [PubMed]
26. Barker TH, Grenett HE, MacEwen MW, Tilden SG, Fuller GM, Settleman J, Woods A, Murphy-Ullrich J, Hagood JS. Thy-1 regulates fibroblast focal adhesions, cytoskeletal organization and migration through modulation of p190 RhoGAP and rho GTPase activity. Exp Cell Res 2004;295:488–496 [PubMed]
27. Kaplan JM, Cook JA, Hake PW, O'Connor M, Burroughs TJ, Zingarelli B. 15-deoxy-delta(12,14)-prostaglandin J(2) (15D-PGJ(2)), a peroxisome proliferator activated receptor gamma ligand, reduces tissue leukosequestration and mortality in endotoxic shock. Shock 2005;24:59–65 [PubMed]
28. Besnard V, Wert SE, Stahlman MT, Postle AD, Xu Y, Ikegami M, Whitsett JA. Deletion of SCAP in alveolar Type II cells influences lung lipid homeostasis and identifies a compensatory role for pulmonary lipofibroblasts. J Biol Chem 2009;284:4018–4030 [PubMed]
29. Imamura M, Inoguchi T, Ikuyama S, Taniguchi S, Kobayashi K, Nakashima N, Nawata H. ADRP stimulates lipid accumulation and lipid droplet formation in murine fibroblasts. Am J Physiol Endocrinol Metab 2002;283:E775–E783 [PubMed]
30. Castrillo A, Tontonoz P. Nuclear receptors in macrophage biology: at the crossroads of lipid metabolism and inflammation. Annu Rev Cell Dev Biol 2004;20:455–480 [PubMed]
31. McGowan S, Jackson SK, Jenkins-Moore M, Dai HH, Chambon P, Snyder JM. Mice bearing deletions of retinoic acid receptors demonstrate reduced lung elastin and alveolar numbers. Am J Respir Cell Mol Biol 2000;23:162–167 [PubMed]
32. Hong I, Rho HS, Kim DH, Lee MO. Activation of LXRalpha induces lipogenesis in HACAT cells. Arch Pharm Res 2010;33:1443–1449 [PubMed]
33. McGowan SE, Torday JS. The pulmonary lipofibroblast (lipid interstitial cell) and its contributions to alveolar development. Annu Rev Physiol 1997;59:43–62 [PubMed]
34. Guthmann F, Haupt R, Looman AC, Spener F, Rustow B. Fatty acid translocase/CD36 mediates the uptake of palmitate by Type II pneumocytes. Am J Physiol 1999;277:L191–L196 [PubMed]
35. Frohnert BI, Hui TY, Bernlohr DA. Identification of a functional peroxisome proliferator–responsive element in the murine fatty acid transport protein gene. J Biol Chem 1999;274:3970–3977 [PubMed]
36. Stahl A. A current review of fatty acid transport proteins (SLC27). Pflugers Arch 2004;447:722–727 [PubMed]
37. Hajri T, Abumrad NA. Fatty acid transport across membranes: relevance to nutrition and metabolic pathology. Annu Rev Nutr 2002;22:383–415 [PubMed]
38. Awonusonu F, Srinivasan S, Strange J, Al-Jumaily W, Bruce MC. Developmental shift in the relative percentages of lung fibroblast subsets: role of apoptosis postseptation. Am J Physiol 1999;277:L848–L859 [PubMed]
39. Tordet C, Marin L, Dameron F. Pulmonary di-and-triacylglycerols during the perinatal development of the rat. Experientia 1981;37:333–334 [PubMed]
40. Torday J, Hua J, Slavin R. Metabolism and fate of neutral lipids of fetal lung fibroblast origin. Biochim Biophys Acta 1995;1254:198–206 [PubMed]
41. Nunez JS, Torday JS. The developing rat lung fibroblast and alveolar Type II cell actively recruit surfactant phospholipid substrate. J Nutr 1995;125(Suppl. 6)1639S–1644S [PubMed]
42. Nicola T, Ambalavanan N, Zhang W, James ML, Rehan VK, Halloran BA, Olave N, Bulger A, Oparil S, Chen YF. Hypoxia-induced inhibition of lung development is attenuated by the peroxisome proliferator–activated receptor–{gamma} agonist rosiglitazone. Am J Physiol Lung Cell Mol Physiol 2011;301:L125–L134 [PubMed]
43. Rehan VK, Sakurai R, Corral J, Krebs M, Ibe B, Ihida-Stansbury K, Torday JS. Antenatally administered PPAR-gamma agonist rosiglitazone prevents hyperoxia-induced neonatal rat lung injury. Am J Physiol Lung Cell Mol Physiol 2010;299:L672–L680 [PubMed]
44. Fujino N, Kubo H, Suzuki T, Ota C, Hegab AE, He M, Suzuki S, Yamada M, Kondo T, Kato H, et al. Isolation of alveolar epithelial Type II progenitor cells from adult human lungs. Lab Invest 2011;91:363–378 [PMC free article] [PubMed]
45. Sanders YY, Pardo A, Selman M, Nuovo GJ, Tollefsbol TO, Siegal GP, Hagood JS. Thy-1 promoter hypermethylation: a novel epigenetic pathogenic mechanism in pulmonary fibrosis. Am J Respir Cell Mol Biol 2008;39:610–618 [PMC free article] [PubMed]
46. Koumas L, Smith TJ, Feldon S, Blumberg N, Phipps RP. Thy-1 expression in human fibroblast subsets defines myofibroblastic or lipofibroblastic phenotypes. Am J Pathol 2003;163:1291–1300 [PubMed]
47. Khoo TK, Coenen MJ, Schiefer AR, Kumar S, Bahn RS. Evidence for enhanced Thy-1 (CD90) expression in orbital fibroblasts of patients with Graves’ ophthalmopathy. Thyroid 2008;18:1291–1296 [PMC free article] [PubMed]
48. Lehmann GM, Woeller CF, Pollock SJ, O'Loughlin CW, Gupta S, Feldon SE, Phipps RP. Novel anti-adipogenic activity produced by human fibroblasts. Am J Physiol Cell Physiol 2010;299:C672–C681 [PubMed]

Articles from American Journal of Respiratory Cell and Molecular Biology are provided here courtesy of American Thoracic Society